RE: Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Response.
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD (MHG, WQL); Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital and Institute, Beijing, China (WCY, WQL); Department of Dermatology, Brown University Warren Alpert Medical School, Providence, RI (WQL); Department of Epidemiology, School of Public Health, Brown University, Providence, RI (WQL). gailm@mail.nih.gov weichengyou@yahoo.com.
Mitchell H
MH
Gail
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD (MHG, WQL); Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital and Institute, Beijing, China (WCY, WQL); Department of Dermatology, Brown University Warren Alpert Medical School, Providence, RI (WQL); Department of Epidemiology, School of Public Health, Brown University, Providence, RI (WQL).
Wei-Cheng
WC
You
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD (MHG, WQL); Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital and Institute, Beijing, China (WCY, WQL); Department of Dermatology, Brown University Warren Alpert Medical School, Providence, RI (WQL); Department of Epidemiology, School of Public Health, Brown University, Providence, RI (WQL).
Wen-Qing
WQ
Li
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D011230:Precancerous Conditions / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000453:epidemiology* / Q000517:prevention & control*
D000900:Anti-Bacterial Agents